BIO

As of 2026-09-10, BIO scores 48out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. BIO trades at $368.75, 82% above the band ceiling.

BIO scores 48 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 48. Its strongest factor is momentum at 61 (solid), where price trend and relative strength are working in its favor, followed by sentiment at 54. The weakest is quality at 36, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 44% of the Healthcare names the model scores.

On valuation, BIO is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 49. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on BIO, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where BIO sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for BIO runs $136.81–$202.92. Current price $368.75 sits 82% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.